An A4-sized informational flyer developed for Hyrimoz (adalimumab), a Sandoz biosimilar medicine used in the treatment of inflammatory and autoimmune conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. The flyer is designed to provide healthcare professionals with quick-reference PBS (Pharmaceutical Benefits Scheme) rheumatology prescribing and authority code information relevant to Hyrimoz prescribing and patient access in Australia.

Leadtime:

• Production: 3-4 working days
• Delivery 3-6 working days